{"id":456566,"date":"2021-03-11T22:30:18","date_gmt":"2021-03-12T03:30:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456566"},"modified":"2021-03-11T22:30:18","modified_gmt":"2021-03-12T03:30:18","slug":"prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/","title":{"rendered":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">March 11, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD),\u00a0today announced\u00a0the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of\u00a0$19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on\u00a0March\u00a012, 2021\u00a0under the ticker symbol &#8220;RXDX&#8221;. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by\u00a0Prometheus, are expected to be\u00a0$190 million. The offering is expected to close on\u00a0March\u00a016, 2021, subject to satisfaction of customary closing conditions.\u00a0In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg\" title=\"(PRNewsfoto\/Prometheus Biosciences, Inc.)\" alt=\"(PRNewsfoto\/Prometheus Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering.<\/p>\n<p>Registration statements relating to the offering have been filed with the\u00a0Securities and Exchange Commission\u00a0and became effective on\u00a0March 11, 2021. The offering will be made only by means of a prospectus. When available, copies of\u00a0the prospectus may be obtained from\u00a0SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, <span class=\"xn-location\">Boston, MA<\/span> 02110, or by telephone at (800) 808-7525, ext. 6105, or by email at <a href=\"mailto:syndicate@svbleerink.com\" rel=\"nofollow\">syndicate@svbleerink.com<\/a>; or from Credit Suisse Securities (<span class=\"xn-location\">USA<\/span>) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, <span class=\"xn-location\">Morrisville, NC<\/span> 27560, or by telephone at (800) 221-1037, or by email at <a href=\"mailto:usa.prospectus@credit-suisse.com\" rel=\"nofollow\">usa.prospectus@credit-suisse.com<\/a>; or from Stifel, Nicolaus &amp; Company, Incorporated, <span class=\"xn-person\">One Montgomery Street<\/span>, Suite 3700, <span class=\"xn-location\">San Francisco, California<\/span> 94104, Attn: Syndicate, or by phone at (415) 364-2720 or by email at <a href=\"mailto:syndprospectus@stifel.com\" rel=\"nofollow\">syndprospectus@stifel.com<\/a>; or from Guggenheim Securities LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, <span class=\"xn-location\">New York, NY<\/span> 10017, by telephone at (212) 518-5548 or by email at <a href=\"mailto:GSEquityProspectusDelivery@guggenheimpartners.com\" rel=\"nofollow\">GSEquityProspectusDelivery@guggenheimpartners.com<\/a>.<\/p>\n<p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <b>About\u00a0Prometheus Biosciences<\/b>\n      <\/p>\n<p>Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company&#8217;s\u00a0precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world&#8217;s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.\u00a0 <\/p>\n<p>Prometheus is headquartered in <span class=\"xn-location\">San Diego<\/span>, CA.\u00a0 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA07770&amp;sd=2021-03-11\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering-301246163.html\">http:\/\/www.prnewswire.com\/news-releases\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering-301246163.html<\/a><\/p>\n<p>SOURCE  Prometheus Biosciences<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA07770&amp;Transmission_Id=202103112226PR_NEWS_USPR_____LA07770&amp;DateId=20210311\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, March 11, 2021 \/PRNewswire\/ &#8212;\u00a0Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD),\u00a0today announced\u00a0the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of\u00a0$19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on\u00a0March\u00a012, 2021\u00a0under the ticker symbol &#8220;RXDX&#8221;. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by\u00a0Prometheus, are expected to be\u00a0$190 million. The offering is expected to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456566","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, March 11, 2021 \/PRNewswire\/ &#8212;\u00a0Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD),\u00a0today announced\u00a0the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of\u00a0$19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on\u00a0March\u00a012, 2021\u00a0under the ticker symbol &#8220;RXDX&#8221;. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by\u00a0Prometheus, are expected to be\u00a0$190 million. The offering is expected to &hellip; Continue reading &quot;Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-12T03:30:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering\",\"datePublished\":\"2021-03-12T03:30:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/\"},\"wordCount\":490,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1232731\\\/Prometheus_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/\",\"name\":\"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1232731\\\/Prometheus_Logo.jpg\",\"datePublished\":\"2021-03-12T03:30:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1232731\\\/Prometheus_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1232731\\\/Prometheus_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, March 11, 2021 \/PRNewswire\/ &#8212;\u00a0Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD),\u00a0today announced\u00a0the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of\u00a0$19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on\u00a0March\u00a012, 2021\u00a0under the ticker symbol &#8220;RXDX&#8221;. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by\u00a0Prometheus, are expected to be\u00a0$190 million. The offering is expected to &hellip; Continue reading \"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-12T03:30:18+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering","datePublished":"2021-03-12T03:30:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/"},"wordCount":490,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/","name":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg","datePublished":"2021-03-12T03:30:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1232731\/Prometheus_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/prometheus-biosciences-announces-upsized-pricing-of-initial-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456566"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456566\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}